{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:36:12Z","timestamp":1794864972901,"version":"4.9.1"},"reference-count":275,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/s41573-023-00746-x","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T12:02:42Z","timestamp":1691150562000},"page":"827-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Strategies to therapeutically modulate cytokine action"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-7448","authenticated-orcid":false,"given":"Warren J.","family":"Leonard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"746_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/0008-8749(74)90066-5","volume":"12","author":"S Cohen","year":"1974","unstructured":"Cohen, S., Bigazzi, P. E. & Yoshida, T. Commentary. Similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol. 12, 150\u2013159 (1974).","journal-title":"Cell Immunol."},{"key":"746_CR2","unstructured":"Keegan, A. D. & Leonard, W. J. in Paul\u2019s Fundamental Immunology 8th edn, ch. 9 (eds Flajnik, M. F., Singh, N. J. & Holland, S. M.) 258\u2013307 (Wolters Kluwer, 2023)."},{"key":"746_CR3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs, A. & Lindenmann, J. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258\u2013267 (1957).","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"746_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nri1684","volume":"5","author":"T Decker","year":"2005","unstructured":"Decker, T., Muller, M. & Stockinger, S. The Yin and Yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 5, 675\u2013687 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"746_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1126\/science.149.3681.310","volume":"149","author":"EF Wheelock","year":"1965","unstructured":"Wheelock, E. F. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 149, 310\u2013311 (1965).","journal-title":"Science"},{"key":"746_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cytogfr.2009.02.004","volume":"20","author":"A Billiau","year":"2009","unstructured":"Billiau, A. & Matthys, P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 20, 97\u2013113 (2009).","journal-title":"Cytokine Growth Factor Rev."},{"key":"746_CR7","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1182\/blood-2007-09-113654","volume":"111","author":"J Chen","year":"2008","unstructured":"Chen, J. et al. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 111, 5163\u20135172 (2008).","journal-title":"Blood"},{"key":"746_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054\u20131061 (2005).","journal-title":"Lancet"},{"key":"746_CR9","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144\u20131148 (2005).","journal-title":"Nature"},{"key":"746_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine, R. L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387\u2013397 (2005).","journal-title":"Cancer Cell"},{"key":"746_CR11","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779\u20131790 (2005).","journal-title":"N. Engl. J. Med."},{"key":"746_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","volume":"22","author":"R Hernandez","year":"2022","unstructured":"Hernandez, R., Poder, J., LaPorte, K. M. & Malek, T. R. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat. Rev. Immunol. 22, 614\u2013628 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"746_CR13","doi-asserted-by":"publisher","first-page":"114112","DOI":"10.1016\/j.addr.2022.114112","volume":"182","author":"PG Holder","year":"2022","unstructured":"Holder, P. G. et al. Engineering interferons and interleukins for cancer immunotherapy. Adv. Drug Deliv. Rev. 182, 114112 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"746_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-022-00557-6","volume":"22","author":"RA Saxton","year":"2022","unstructured":"Saxton, R. A., Glassman, C. R. & Garcia, K. C. Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. Drug Discov. 22, 21\u201337 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"746_CR15","doi-asserted-by":"publisher","first-page":"eabo5409","DOI":"10.1126\/scitranslmed.abo5409","volume":"14","author":"ME Raeber","year":"2022","unstructured":"Raeber, M. E., Sahin, D. & Boyman, O. Interleukin-2-based therapies in cancer. Sci. Transl. Med. 14, eabo5409 (2022).","journal-title":"Sci. Transl. Med."},{"key":"746_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper, D. J. & Balkwill, F. R. Harnessing cytokines and chemokines for cancer therapy. Nat. Rev. Clin. Oncol. 19, 237\u2013253 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"746_CR17","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/pro.5560020902","volume":"2","author":"A Wlodawer","year":"1993","unstructured":"Wlodawer, A., Pavlovsky, A. & Gustchina, A. Hematopoietic cytokines: similarities and differences in the structures, with implications for receptor binding. Protein Sci. 2, 1373\u20131382 (1993).","journal-title":"Protein Sci."},{"key":"746_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","volume":"17","author":"RR Goel","year":"2021","unstructured":"Goel, R. R., Kotenko, S. V. & Kaplan, M. J. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 17, 349\u2013362 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"746_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41584-019-0277-8","volume":"15","author":"CA Dinarello","year":"2019","unstructured":"Dinarello, C. A. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat. Rev. Rheumatol. 15, 612\u2013632 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"746_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.1944","volume":"11","author":"MF Nold","year":"2010","unstructured":"Nold, M. F. et al. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11, 1014\u20131022 (2010).","journal-title":"Nat. Immunol."},{"key":"746_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/ni.3103","volume":"16","author":"CA Nold-Petry","year":"2015","unstructured":"Nold-Petry, C. A. et al. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat. Immunol. 16, 354\u2013365 (2015).","journal-title":"Nat. Immunol."},{"key":"746_CR22","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.1121534109","volume":"109","author":"FL van de Veerdonk","year":"2012","unstructured":"van de Veerdonk, F. L. et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl Acad. Sci. USA 109, 3001\u20133005 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/jmcb\/mjw006","volume":"8","author":"J Mora","year":"2016","unstructured":"Mora, J. et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J. Mol. Cell Biol. 8, 426\u2013438 (2016).","journal-title":"J. Mol. Cell Biol."},{"key":"746_CR24","doi-asserted-by":"publisher","first-page":"155824","DOI":"10.1016\/j.cyto.2022.155824","volume":"152","author":"DM de Graaf","year":"2022","unstructured":"de Graaf, D. M., Teufel, L. U., Joosten, L. A. B. & Dinarello, C. A. Interleukin-38 in health and disease. Cytokine 152, 155824 (2022).","journal-title":"Cytokine"},{"key":"746_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev-immunol-101819-092536","volume":"39","author":"S Majumder","year":"2021","unstructured":"Majumder, S. & McGeachy, M. J. IL-17 in the pathogenesis of disease: good intentions gone awry. Annu. Rev. Immunol. 39, 537\u2013556 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"746_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","volume":"23","author":"KHG Mills","year":"2022","unstructured":"Mills, K. H. G. IL-17 and IL-17-producing cells in protection versus pathology. Nat. Rev. Immunol. 23, 38\u201354 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"746_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41586-022-05116-y","volume":"609","author":"SC Wilson","year":"2022","unstructured":"Wilson, S. C. et al. Organizing structural principles of the IL-17 ligand-receptor axis. Nature 609, 622\u2013629 (2022).","journal-title":"Nature"},{"key":"746_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0969-2126(93)90029-G","volume":"1","author":"J Murray-Rust","year":"1993","unstructured":"Murray-Rust, J. et al. Topological similarities in TGF-beta 2, PDGF-BB and NGF define a superfamily of polypeptide growth factors. Structure 1, 153\u2013159 (1993).","journal-title":"Structure"},{"key":"746_CR29","doi-asserted-by":"publisher","first-page":"a028522","DOI":"10.1101\/cshperspect.a028522","volume":"10","author":"L Monin","year":"2018","unstructured":"Monin, L. & Gaffen, S. L. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb. Perspect. Biol. 10, a028522 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"746_CR30","doi-asserted-by":"publisher","first-page":"a028431","DOI":"10.1101\/cshperspect.a028431","volume":"10","author":"D Wallach","year":"2018","unstructured":"Wallach, D. The tumor necrosis factor family: family conventions and private idiosyncrasies. Cold Spring Harb. Perspect. Biol. 10, a028431 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"746_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1126\/science.1549776","volume":"255","author":"AM de Vos","year":"1992","unstructured":"de Vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306\u2013312 (1992). Provides the structure of a type I cytokine\u2013type I cytokine receptor complex, revealing receptor homodimerization for the growth hormone system.","journal-title":"Science"},{"key":"746_CR32","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.1073\/pnas.87.18.6934","volume":"87","author":"JF Bazan","year":"1990","unstructured":"Bazan, J. F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl Acad. Sci. USA 87, 6934\u20136938 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.immunol.24.021605.090616","volume":"27","author":"X Wang","year":"2009","unstructured":"Wang, X., Lupardus, P., Laporte, S. L. & Garcia, K. C. Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27, 29\u201360 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"746_CR34","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.12688\/f1000research.12202.1","volume":"6","author":"R Spolski","year":"2017","unstructured":"Spolski, R., Gromer, D. & Leonard, W. J. The gamma c family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response. F1000Res 6, 1872 (2017).","journal-title":"F1000Res"},{"key":"746_CR35","doi-asserted-by":"publisher","first-page":"a028449","DOI":"10.1101\/cshperspect.a028449","volume":"10","author":"JX Lin","year":"2018","unstructured":"Lin, J. X. & Leonard, W. J. The common cytokine receptor gamma chain family of cytokines. Cold Spring Harb. Perspect. Biol. 10, a028449 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"746_CR36","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648\u2013659 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"746_CR37","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","volume":"50","author":"WJ Leonard","year":"2019","unstructured":"Leonard, W. J., Lin, J. X. & O\u2019Shea, J. J. The \u03b3c family of cytokines: basic biology to therapeutic ramifications. Immunity 50, 832\u2013850 (2019).","journal-title":"Immunity"},{"key":"746_CR38","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1126\/science.1109745","volume":"308","author":"M Rickert","year":"2005","unstructured":"Rickert, M., Wang, X., Boulanger, M. J., Goriatcheva, N. & Garcia, K. C. The structure of interleukin-2 complexed with its alpha receptor. Science 308, 1477\u20131480 (2005).","journal-title":"Science"},{"key":"746_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0092-8674(93)90167-O","volume":"73","author":"M Noguchi","year":"1993","unstructured":"Noguchi, M. et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147\u2013157 (1993). Demonstrates that IL-2R\u03b3 mutations result in X-SCID and predicted the existence of the \u03b3c family of cytokines.","journal-title":"Cell"},{"key":"746_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.med.47.1.229","volume":"47","author":"WJ Leonard","year":"1996","unstructured":"Leonard, W. J. The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Annu. Rev. Med. 47, 229\u2013239 (1996).","journal-title":"Annu. Rev. Med."},{"key":"746_CR41","doi-asserted-by":"publisher","first-page":"15061","DOI":"10.1038\/nrdp.2015.61","volume":"1","author":"A Fischer","year":"2015","unstructured":"Fischer, A., Notarangelo, L. D., Neven, B., Cavazzana, M. & Puck, J. M. Severe combined immunodeficiencies and related disorders. Nat. Rev. Dis. Prim. 1, 15061 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"746_CR42","doi-asserted-by":"publisher","first-page":"eaal1253","DOI":"10.1126\/scisignal.aal1253","volume":"11","author":"P Gonnord","year":"2018","unstructured":"Gonnord, P. et al. A hierarchy of affinities between cytokine receptors and the common gamma chain leads to pathway cross-talk. Sci. Signal. 11, eaal1253 (2018).","journal-title":"Sci. Signal."},{"key":"746_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0092-8674(89)90121-9","volume":"57","author":"WE Paul","year":"1989","unstructured":"Paul, W. E. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell 57, 521\u2013524 (1989).","journal-title":"Cell"},{"key":"746_CR44","doi-asserted-by":"publisher","first-page":"29355","DOI":"10.1074\/jbc.R200003200","volume":"277","author":"K Ozaki","year":"2002","unstructured":"Ozaki, K. & Leonard, W. J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 277, 29355\u201329358 (2002).","journal-title":"J. Biol. Chem."},{"key":"746_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.amjms.2016.10.009","volume":"353","author":"A Nekoui","year":"2017","unstructured":"Nekoui, A. & Blaise, G. Erythropoietin and nonhematopoietic effects. Am. J. Med. Sci. 353, 76\u201381 (2017).","journal-title":"Am. J. Med. Sci."},{"key":"746_CR46","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1073\/pnas.0400339101","volume":"101","author":"J Cote-Sierra","year":"2004","unstructured":"Cote-Sierra, J. et al. Interleukin 2 plays a central role in Th2 differentiation. Proc. Natl Acad. Sci. USA 101, 3880\u20133885 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR47","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/ni.1656","volume":"9","author":"W Liao","year":"2008","unstructured":"Liao, W. et al. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor \u03b1-chain expression. Nat. Immunol. 9, 1288\u20131296 (2008).","journal-title":"Nat. Immunol."},{"key":"746_CR48","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/ni.2030","volume":"12","author":"W Liao","year":"2011","unstructured":"Liao, W., Lin, J. X., Wang, L., Li, P. & Leonard, W. J. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat. Immunol. 12, 551\u2013559 (2011).","journal-title":"Nat. Immunol."},{"key":"746_CR49","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","volume":"26","author":"A Laurence","year":"2007","unstructured":"Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371\u2013381 (2007).","journal-title":"Immunity"},{"key":"746_CR50","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1073\/pnas.1301138111","volume":"111","author":"W Liao","year":"2014","unstructured":"Liao, W. et al. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc. Natl Acad. Sci. USA 111, 3508\u20133513 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283\u2013294 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"746_CR52","doi-asserted-by":"publisher","first-page":"eaat1482","DOI":"10.1126\/sciimmunol.aat1482","volume":"3","author":"AK Abbas","year":"2018","unstructured":"Abbas, A. K., Trotta, E., Simeonov, D. R., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).","journal-title":"Sci. Immunol."},{"key":"746_CR53","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41584-021-00707-x","volume":"17","author":"AGA Kolios","year":"2021","unstructured":"Kolios, A. G. A., Tsokos, G. C. & Klatzmann, D. Interleukin-2 and regulatory T cells in rheumatic diseases. Nat. Rev. Rheumatol. 17, 749\u2013766 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"746_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.ai.2022.09.002","volume":"156","author":"TA Waldmann","year":"2022","unstructured":"Waldmann, T. A., Waldmann, R., Lin, J.-X. & Leonard, W. J. The implications of IL-15 trans-presentation on the immune response. Adv. Immunol. 156, 103\u2013132 (2022).","journal-title":"Adv. Immunol."},{"key":"746_CR55","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/3877","volume":"20","author":"A Puel","year":"1998","unstructured":"Puel, A., Ziegler, S. F., Buckley, R. H. & Leonard, W. J. Defective IL7R expression in T\u2212B+NK+ severe combined immunodeficiency. Nat. Genet. 20, 394\u2013397 (1998).","journal-title":"Nat. Genet."},{"key":"746_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.12703\/r\/10-71","volume":"10","author":"AD Keegan","year":"2021","unstructured":"Keegan, A. D., Leonard, W. J. & Zhu, J. Recent advances in understanding the role of IL-4 signaling. Fac. Rev. 10, 71 (2021).","journal-title":"Fac. Rev."},{"key":"746_CR57","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1002\/j.1460-2075.1992.tb05239.x","volume":"11","author":"T Hara","year":"1992","unstructured":"Hara, T. & Miyajima, A. Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3). EMBO J. 11, 1875\u20131884 (1992).","journal-title":"EMBO J."},{"key":"746_CR58","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/369330a0","volume":"369","author":"Y Nakamura","year":"1994","unstructured":"Nakamura, Y. et al. Heterodimerization of the IL-2 receptor \u03b2- and \u03b3-chain cytoplasmic domains is required for signalling. Nature 369, 330\u2013333 (1994). With ref. 59, one of two papers demonstrating that IL-2 signalling requires the dimerization of the IL-2R\u03b2 and \u03b3c cytoplasmic domains. Such dimerization has informed strategies related to IL-2 therapy.","journal-title":"Nature"},{"key":"746_CR59","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/369333a0","volume":"369","author":"BH Nelson","year":"1994","unstructured":"Nelson, B. H., Lord, J. D. & Greenberg, P. D. Cytoplasmic domains of the interleukin-2 receptor \u03b2 and \u03b3chains mediate the signal for T-cell proliferation. Nature 369, 333\u2013336 (1994). With ref. 58, one of two papers demonstrating that IL-2 signalling requires the dimerization of the IL-2R\u03b2 and \u03b3c cytoplasmic domains. Such dimerization has informed strategies related to IL-2 therapy.","journal-title":"Nature"},{"key":"746_CR60","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","volume":"16","author":"WJ Leonard","year":"1998","unstructured":"Leonard, W. J. & O\u2019Shea, J. J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16, 293\u2013322 (1998).","journal-title":"Annu. Rev. Immunol."},{"key":"746_CR61","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.22882","volume":"6","author":"I Moraga","year":"2017","unstructured":"Moraga, I. et al. Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. eLife 6, e22882 (2017).","journal-title":"eLife"},{"key":"746_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","volume":"377","author":"P Macchi","year":"1995","unstructured":"Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65\u201368 (1995).","journal-title":"Nature"},{"key":"746_CR63","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.270.5237.797","volume":"270","author":"SM Russell","year":"1995","unstructured":"Russell, S. M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797\u2013800 (1995). Predicts that JAK3 inhibitors would be immunosuppressive, helping to launch the field of development of JAK inhibitors.","journal-title":"Science"},{"key":"746_CR64","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","volume":"25","author":"Y Minegishi","year":"2006","unstructured":"Minegishi, Y. et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745\u2013755 (2006).","journal-title":"Immunity"},{"key":"746_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225289","volume":"15","author":"Z Li","year":"2020","unstructured":"Li, Z., Rotival, M., Patin, E., Michel, F. & Pellegrini, S. Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage. PLoS ONE 15, e0225289 (2020).","journal-title":"PLoS ONE"},{"key":"746_CR66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.7604283","volume":"269","author":"TS Migone","year":"1995","unstructured":"Migone, T. S. et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269, 79\u201381 (1995).","journal-title":"Science"},{"key":"746_CR67","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1126\/science.7569929","volume":"269","author":"NN Danial","year":"1995","unstructured":"Danial, N. N., Pernis, A. & Rothman, P. B. Jak-STAT signaling induced by the v-abl oncogene. Science 269, 1875\u20131877 (1995).","journal-title":"Science"},{"key":"746_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00062752-200701000-00009","volume":"14","author":"RL Levine","year":"2007","unstructured":"Levine, R. L. & Gilliland, D. G. JAK-2 mutations and their relevance to myeloproliferative disease. Curr. Opin. Hematol. 14, 43\u201347 (2007).","journal-title":"Curr. Opin. Hematol."},{"key":"746_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160339","volume":"11","author":"BK Sathyanarayana","year":"2016","unstructured":"Sathyanarayana, B. K., Li, P., Lin, J. X., Leonard, W. J. & Lee, B. Molecular models of STAT5A tetramers complexed to DNA predict relative genome-wide frequencies of the spacing between the two dimer binding motifs of the tetramer binding sites. PLoS ONE 11, e0160339 (2016).","journal-title":"PLoS ONE"},{"key":"746_CR70","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/ni.2794","volume":"15","author":"A Begitt","year":"2014","unstructured":"Begitt, A. et al. STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling. Nat. Immunol. 15, 168\u2013176 (2014).","journal-title":"Nat. Immunol."},{"key":"746_CR71","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.immuni.2012.02.017","volume":"36","author":"JX Lin","year":"2012","unstructured":"Lin, J. X. et al. Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 36, 586\u2013599 (2012).","journal-title":"Immunity"},{"key":"746_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01477-5","volume":"8","author":"JX Lin","year":"2017","unstructured":"Lin, J. X. et al. Critical functions for STAT5 tetramers in the maturation and survival of natural killer cells. Nat. Commun. 8, 1320 (2017).","journal-title":"Nat. Commun."},{"key":"746_CR73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116256118","volume":"118","author":"KL Monaghan","year":"2021","unstructured":"Monaghan, K. L. et al. Tetramerization of STAT5 promotes autoimmune-mediated neuroinflammation. Proc. Natl Acad. Sci. USA 118, e2116256118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR74","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1073\/pnas.93.5.2077","volume":"93","author":"MC Friedmann","year":"1996","unstructured":"Friedmann, M. C., Migone, T. S., Russell, S. M. & Leonard, W. J. Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. Proc. Natl Acad. Sci. USA 93, 2077\u20132082 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR75","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/1074-7613(95)90141-8","volume":"2","author":"JX Lin","year":"1995","unstructured":"Lin, J. X. et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2, 331\u2013339 (1995).","journal-title":"Immunity"},{"key":"746_CR76","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1182\/blood-2006-10-054973","volume":"109","author":"R Zeng","year":"2007","unstructured":"Zeng, R. et al. The molecular basis of IL-21\u2013mediated proliferation. Blood 109, 4135\u20134142 (2007).","journal-title":"Blood"},{"key":"746_CR77","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1128\/MCB.18.11.6416","volume":"18","author":"TS Migone","year":"1998","unstructured":"Migone, T. S. et al. Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation. Mol. Cell Biol. 18, 6416\u20136422 (1998).","journal-title":"Mol. Cell Biol."},{"key":"746_CR78","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.immuni.2013.02.011","volume":"38","author":"CK Wan","year":"2013","unstructured":"Wan, C. K. et al. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 38, 514\u2013527 (2013).","journal-title":"Immunity"},{"key":"746_CR79","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0092-8674(95)90311-9","volume":"82","author":"Z Wen","year":"1995","unstructured":"Wen, Z., Zhong, Z. & Darnell, J. E. Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241\u2013250 (1995).","journal-title":"Cell"},{"key":"746_CR80","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1093\/nar\/25.11.2062","volume":"25","author":"Z Wen","year":"1997","unstructured":"Wen, Z. & Darnell, J. E. Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 25, 2062\u20132067 (1997).","journal-title":"Nucleic Acids Res."},{"key":"746_CR81","doi-asserted-by":"publisher","first-page":"9373","DOI":"10.1073\/pnas.0903487106","volume":"106","author":"H Cheon","year":"2009","unstructured":"Cheon, H. & Stark, G. R. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl Acad. Sci. USA 106, 9373\u20139378 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR82","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1158\/0008-5472.939.65.3","volume":"65","author":"J Yang","year":"2005","unstructured":"Yang, J. et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65, 939\u2013947 (2005).","journal-title":"Cancer Res."},{"key":"746_CR83","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/cr.2008.41","volume":"18","author":"J Yang","year":"2008","unstructured":"Yang, J. & Stark, G. R. Roles of unphosphorylated STATs in signaling. Cell Res. 18, 443\u2013451 (2008).","journal-title":"Cell Res."},{"key":"746_CR84","doi-asserted-by":"publisher","first-page":"10213","DOI":"10.1073\/pnas.1221243110","volume":"110","author":"X Hu","year":"2013","unstructured":"Hu, X. et al. Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth. Proc. Natl Acad. Sci. USA 110, 10213\u201310218 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR85","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1126\/science.1171721","volume":"324","author":"DJ Gough","year":"2009","unstructured":"Gough, D. J. et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324, 1713\u20131716 (2009).","journal-title":"Science"},{"key":"746_CR86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.smim.2013.12.005","volume":"26","author":"JA Meier","year":"2014","unstructured":"Meier, J. A. & Larner, A. C. Toward a new STATe: the role of STATs in mitochondrial function. Semin. Immunol. 26, 20\u201328 (2014).","journal-title":"Semin. Immunol."},{"key":"746_CR87","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0952-7915(00)00228-4","volume":"13","author":"M Gadina","year":"2001","unstructured":"Gadina, M. et al. Signaling by type I and II cytokine receptors: ten years after. Curr. Opin. Immunol. 13, 363\u2013373 (2001).","journal-title":"Curr. Opin. Immunol."},{"key":"746_CR88","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nri1667","volume":"5","author":"K Shuai","year":"2005","unstructured":"Shuai, K. & Liu, B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol. 5, 593\u2013605 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"746_CR89","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cytogfr.2006.07.003","volume":"17","author":"HP Kim","year":"2006","unstructured":"Kim, H. P., Imbert, J. & Leonard, W. J. Both integrated and differential regulation of components of the IL-2\/IL-2 receptor system. Cytokine Growth Factor Rev. 17, 349\u2013366 (2006).","journal-title":"Cytokine Growth Factor Rev."},{"key":"746_CR90","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/all.15576","volume":"78","author":"LEM Heeb","year":"2022","unstructured":"Heeb, L. E. M. & Boyman, O. Comprehensive analysis of human IL-4 receptor subunits shows compartmentalization in steady state and dupilumab treatment. Allergy 78, 1073\u20131087 (2022).","journal-title":"Allergy"},{"key":"746_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/76923","volume":"1","author":"A Pandey","year":"2000","unstructured":"Pandey, A. et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat. Immunol. 1, 59\u201364 (2000).","journal-title":"Nat. Immunol."},{"key":"746_CR92","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1084\/jem.192.5.659","volume":"192","author":"LS Park","year":"2000","unstructured":"Park, L. S. et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. J. Exp. Med. 192, 659\u2013670 (2000).","journal-title":"J. Exp. Med."},{"key":"746_CR93","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","volume":"23","author":"R Ebina-Shibuya","year":"2022","unstructured":"Ebina-Shibuya, R. & Leonard, W. J. Role of thymic stromal lymphopoietin in allergy and beyond. Nat. Rev. Immunol. 23, 24\u201337 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"746_CR94","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00277-017-2953-6","volume":"96","author":"F Rodeghiero","year":"2017","unstructured":"Rodeghiero, F. & Carli, G. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Ann. Hematol. 96, 1421\u20131434 (2017).","journal-title":"Ann. Hematol."},{"key":"746_CR95","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.drudis.2014.09.003","volume":"20","author":"MS Kinch","year":"2015","unstructured":"Kinch, M. S. An overview of FDA-approved biologics medicines. Drug Discov. Today 20, 393\u2013398 (2015).","journal-title":"Drug Discov. Today"},{"key":"746_CR96","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","volume":"25","author":"BC Kieseier","year":"2011","unstructured":"Kieseier, B. C. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 25, 491\u2013502 (2011).","journal-title":"CNS Drugs"},{"key":"746_CR97","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-199243010-00008","volume":"43","author":"PA Todd","year":"1992","unstructured":"Todd, P. A. & Goa, K. L. Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs 43, 111\u2013122 (1992).","journal-title":"Drugs"},{"key":"746_CR98","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13\u201325 (2013).","journal-title":"Immunity"},{"key":"746_CR99","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1084\/jem.161.5.1169","volume":"161","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M. & Schwarz, S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161, 1169\u20131188 (1985). Provides evidence that IL-2 in animal studies had translational potential as an antitumour therapeutic, with later approval by the FDA for metastatic melanoma and renal cell carcinoma.","journal-title":"J. Exp. Med."},{"key":"746_CR100","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451\u20135458 (2014).","journal-title":"J. Immunol."},{"key":"746_CR101","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","volume":"17","author":"TR Malek","year":"2002","unstructured":"Malek, T. R., Yu, A., Vincek, V., Scibelli, P. & Kong, L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17, 167\u2013178 (2002).","journal-title":"Immunity"},{"key":"746_CR102","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","volume":"11","author":"TA Waldmann","year":"2020","unstructured":"Waldmann, T. A., Dubois, S., Miljkovic, M. D. & Conlon, K. C. IL-15 in the combination immunotherapy of cancer. Front. Immunol. 11, 868 (2020).","journal-title":"Front. Immunol."},{"key":"746_CR103","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","volume":"111","author":"CS Hinrichs","year":"2008","unstructured":"Hinrichs, C. S. et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111, 5326\u20135333 (2008).","journal-title":"Blood"},{"key":"746_CR104","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20041057","volume":"201","author":"R Zeng","year":"2005","unstructured":"Zeng, R. et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201, 139\u2013148 (2005).","journal-title":"J. Exp. Med."},{"key":"746_CR105","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/1380-2933(95)00009-7","volume":"1","author":"ET Harvill","year":"1995","unstructured":"Harvill, E. T. & Morrison, S. L. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1, 95\u2013105 (1995).","journal-title":"Immunotechnology"},{"key":"746_CR106","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s00262-003-0454-z","volume":"53","author":"Z Yao","year":"2004","unstructured":"Yao, Z., Dai, W., Perry, J., Brechbiel, M. W. & Sung, C. Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol. Immunother. 53, 404\u2013410 (2004).","journal-title":"Cancer Immunol. Immunother."},{"key":"746_CR107","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65777","volume":"10","author":"CR Glassman","year":"2021","unstructured":"Glassman, C. R. et al. Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist. eLife 10, e65777 (2021). Describes an IL-2 partial agonist that favours Treg cell expansion.","journal-title":"eLife"},{"key":"746_CR108","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41586-021-03861-0","volume":"597","author":"F Mo","year":"2021","unstructured":"Mo, F. et al. An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature 597, 544\u2013548 (2021). Describes an IL-2 partial agonist that promotes a CD8+ T stem cell-like phenotype in vitro.","journal-title":"Nature"},{"key":"746_CR109","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41551-020-00627-3","volume":"5","author":"A Ishihara","year":"2021","unstructured":"Ishihara, A. et al. Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat. Biomed. Eng. 5, 387\u2013398 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"746_CR110","first-page":"343","volume":"8","author":"RJ Goodson","year":"1990","unstructured":"Goodson, R. J. & Katre, N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 8, 343\u2013346 (1990).","journal-title":"Biotechnology"},{"key":"746_CR111","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4049\/jimmunol.144.1.209","volume":"144","author":"NV Katre","year":"1990","unstructured":"Katre, N. V. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 144, 209\u2013213 (1990).","journal-title":"J. Immunol."},{"key":"746_CR112","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"DH Charych","year":"2016","unstructured":"Charych, D. H. et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680\u2013690 (2016).","journal-title":"Clin. Cancer Res."},{"key":"746_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14471-1","volume":"11","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat. Commun. 11, 661 (2020).","journal-title":"Nat. Commun."},{"key":"746_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12901-3","volume":"11","author":"G Parisi","year":"2020","unstructured":"Parisi, G. et al. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat. Commun. 11, 660 (2020).","journal-title":"Nat. Commun."},{"key":"746_CR115","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41587-022-01390-3","volume":"40","author":"E Dolgin","year":"2022","unstructured":"Dolgin, E. IL-2 upgrades show promise at ASCO. Nat. Biotechnol. 40, 986\u2013988 (2022).","journal-title":"Nat. Biotechnol."},{"key":"746_CR116","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","volume":"5","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat. Biomed. Eng. 5, 1288\u20131305 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"746_CR117","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.jtauto.2021.100103","volume":"4","author":"N Dixit","year":"2021","unstructured":"Dixit, N. et al. NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl. Autoimmun. 4, 100103 (2021).","journal-title":"J. Transl. Autoimmun."},{"key":"746_CR118","first-page":"100035","volume":"4","author":"IS Pires","year":"2021","unstructured":"Pires, I. S., Hammond, P. T. & Irvine, D. J. Engineering strategies for immunomodulatory cytokine therapies - challenges and clinical progress. Adv. Ther. 4, 100035 (2021).","journal-title":"Adv. Ther."},{"key":"746_CR119","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1158\/2326-6066.CIR-21-0831","volume":"10","author":"CJ Nirschl","year":"2022","unstructured":"Nirschl, C. J. et al. Discovery of a conditionally activated IL-2 that promotes antitumor immunity and induces tumor regression. Cancer Immunol. Res. 10, 581\u2013596 (2022). Describes an IL-2 pro-drug that is activated by protease cleavage in the TME.","journal-title":"Cancer Immunol. Res."},{"key":"746_CR120","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0705","author":"CJ Nirschl","year":"2023","unstructured":"Nirschl, C. J. et al. mWTX-330, an IL 12 INDUKINE molecule, activates and reshapes tumor-infiltrating CD8+ T and NK cells to generate antitumor immunity. Cancer Immunol. Res. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0705 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"746_CR121","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41551-021-00831-9","volume":"6","author":"Y Agarwal","year":"2022","unstructured":"Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129\u2013143 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"746_CR122","doi-asserted-by":"publisher","first-page":"eaaw5680","DOI":"10.1126\/scitranslmed.aaw5680","volume":"11","author":"EA Chiocca","year":"2019","unstructured":"Chiocca, E. A. et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci. Transl. Med. 11, eaaw5680 (2019).","journal-title":"Sci. Transl. Med."},{"key":"746_CR123","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1126\/science.1122927","volume":"311","author":"O Boyman","year":"2006","unstructured":"Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924\u20131927 (2006). A study using distinctive anti-IL-2 antibodies to stimulate intermediate- versus high-affinity IL-2 receptors, and differentially affecting Treg cells and Teff cells.","journal-title":"Science"},{"key":"746_CR124","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2015.04.015","volume":"42","author":"JB Spangler","year":"2015","unstructured":"Spangler, J. B. et al. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity 42, 815\u2013825 (2015).","journal-title":"Immunity"},{"key":"746_CR125","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.4049\/jimmunol.1800578","volume":"201","author":"JB Spangler","year":"2018","unstructured":"Spangler, J. B. et al. Engineering a single-agent cytokine\/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy. J. Immunol. 201, 2094\u20132106 (2018).","journal-title":"J. Immunol."},{"key":"746_CR126","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","volume":"24","author":"E Trotta","year":"2018","unstructured":"Trotta, E. et al. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nat. Med. 24, 1005\u20131014 (2018).","journal-title":"Nat. Med."},{"key":"746_CR127","doi-asserted-by":"publisher","first-page":"eabb9283","DOI":"10.1126\/scitranslmed.abb9283","volume":"12","author":"U Karakus","year":"2020","unstructured":"Karakus, U. et al. Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species. Sci. Transl. Med. 12, eabb9283 (2020).","journal-title":"Sci. Transl. Med."},{"key":"746_CR128","doi-asserted-by":"publisher","first-page":"111478","DOI":"10.1016\/j.celrep.2022.111478","volume":"41","author":"D VanDyke","year":"2022","unstructured":"VanDyke, D. et al. Engineered human cytokine\/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Rep. 41, 111478 (2022).","journal-title":"Cell Rep."},{"key":"746_CR129","doi-asserted-by":"publisher","first-page":"367ra166","DOI":"10.1126\/scitranslmed.aag3187","volume":"8","author":"N Arenas-Ramirez","year":"2016","unstructured":"Arenas-Ramirez, N. et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci. Transl. Med. 8, 367ra166 (2016).","journal-title":"Sci. Transl. Med."},{"key":"746_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20220-1","volume":"11","author":"D Sahin","year":"2020","unstructured":"Sahin, D. et al. An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer. Nat. Commun. 11, 6440 (2020).","journal-title":"Nat. Commun."},{"key":"746_CR131","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.1073\/pnas.2000419117","volume":"117","author":"VS De Paula","year":"2020","unstructured":"De Paula, V. S. et al. Interleukin-2 druggability is modulated by global conformational transitions controlled by a helical capping switch. Proc. Natl Acad. Sci. USA 117, 7183\u20137192 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR132","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037\u20131042 (2018). Describes the orthogonal IL-2\/IL-2 receptor system.","journal-title":"Science"},{"key":"746_CR133","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139991","volume":"131","author":"T Hirai","year":"2021","unstructured":"Hirai, T. et al. Selective expansion of regulatory T cells using an orthogonal IL-2\/IL-2 receptor system facilitates transplantation tolerance. J. Clin. Invest. 131, e139991 (2021).","journal-title":"J. Clin. Invest."},{"key":"746_CR134","doi-asserted-by":"publisher","first-page":"eabg7565","DOI":"10.1126\/scitranslmed.abg7565","volume":"13","author":"PJ Aspuria","year":"2021","unstructured":"Aspuria, P. J. et al. An orthogonal IL-2 and IL-2Rbeta system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. Sci. Transl. Med. 13, eabg7565 (2021).","journal-title":"Sci. Transl. Med."},{"key":"746_CR135","doi-asserted-by":"publisher","first-page":"eabg6986","DOI":"10.1126\/scitranslmed.abg6986","volume":"13","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci. Transl. Med. 13, eabg6986 (2021).","journal-title":"Sci. Transl. Med."},{"key":"746_CR136","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi, A. et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360\u2013365 (2022).","journal-title":"Nature"},{"key":"746_CR137","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352\u2013359 (2018).","journal-title":"Nat. Med."},{"key":"746_CR138","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1073\/pnas.85.20.7709","volume":"85","author":"L Collins","year":"1988","unstructured":"Collins, L. et al. Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 85, 7709\u20137713 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR139","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1073\/pnas.88.11.4636","volume":"88","author":"K Sauve","year":"1991","unstructured":"Sauve, K. et al. Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 88, 4636\u20134640 (1991). Development of \u2018no-\u03b1\u2019 muteins of IL-2 that retain biological activity.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR140","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1002\/j.1460-2075.1993.tb06206.x","volume":"12","author":"SM Zurawski","year":"1993","unstructured":"Zurawski, S. M. et al. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor. EMBO J. 12, 5113\u20135119 (1993).","journal-title":"EMBO J."},{"key":"746_CR141","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/81199","volume":"18","author":"AB Shanafelt","year":"2000","unstructured":"Shanafelt, A. B. et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. 18, 1197\u20131202 (2000). Describes an early IL-2 mutein with antitumour activity in animal models.","journal-title":"Nat. Biotechnol."},{"key":"746_CR142","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.4049\/jimmunol.1201895","volume":"190","author":"T Carmenate","year":"2013","unstructured":"Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230\u20136238 (2013).","journal-title":"J. Immunol."},{"key":"746_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","volume":"95","author":"LB Peterson","year":"2018","unstructured":"Peterson, L. B. et al. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. J. Autoimmun. 95, 1\u201314 (2018).","journal-title":"J. Autoimmun."},{"key":"746_CR144","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10975","volume":"484","author":"AM Levin","year":"2012","unstructured":"Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019. Nature 484, 529\u2013533 (2012). Describes super-IL-2.","journal-title":"Nature"},{"key":"746_CR145","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nchembio.1096","volume":"8","author":"IS Junttila","year":"2012","unstructured":"Junttila, I. S. et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat. Chem. Biol. 8, 990\u2013998 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"746_CR146","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.immuni.2015.04.018","volume":"42","author":"S Mitra","year":"2015","unstructured":"Mitra, S. et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42, 826\u2013838 (2015). Describes an IL-2\/IL-15 antagonist and IL-2 partial agonists.","journal-title":"Immunity"},{"key":"746_CR147","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/sj.bjp.0707672","volume":"153","author":"PG Strange","year":"2008","unstructured":"Strange, P. G. Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br. J. Pharmacol. 153, 1353\u20131363 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"746_CR148","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1073\/pnas.0511161103","volume":"103","author":"DJ Stauber","year":"2006","unstructured":"Stauber, D. J., Debler, E. W., Horton, P. A., Smith, K. A. & Wilson, I. A. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc. Natl Acad. Sci. USA 103, 2788\u20132793 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR149","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1006\/abbi.1993.1608","volume":"307","author":"P Buchli","year":"1993","unstructured":"Buchli, P. & Ciardelli, T. Structural and biologic properties of a human aspartic acid-126 interleukin-2 analog. Arch. Biochem. Biophys. 307, 411\u2013415 (1993).","journal-title":"Arch. Biochem. Biophys."},{"key":"746_CR150","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1073\/pnas.1920413117","volume":"117","author":"D Hermans","year":"2020","unstructured":"Hermans, D. et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity. Proc. Natl Acad. Sci. USA 117, 6047\u20136055 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR151","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.aaf6284","volume":"354","author":"M Peng","year":"2016","unstructured":"Peng, M. et al. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 354, 481\u2013484 (2016).","journal-title":"Science"},{"key":"746_CR152","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.4049\/jimmunol.1700433","volume":"200","author":"T Carmenate","year":"2018","unstructured":"Carmenate, T. et al. Blocking IL-2 signal in vivo with an IL-2 antagonist reduces tumor growth through the control of regulatory T cells. J. Immunol. 200, 3475\u20133484 (2018).","journal-title":"J. Immunol."},{"key":"746_CR153","doi-asserted-by":"publisher","first-page":"eade5686","DOI":"10.1126\/sciimmunol.ade5686","volume":"7","author":"S Gaggero","year":"2022","unstructured":"Gaggero, S. et al. IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein. Sci. Immunol. 7, eade5686 (2022). Describes a pH-selective mutein that is activated in the acidic TME.","journal-title":"Sci. Immunol."},{"key":"746_CR154","doi-asserted-by":"publisher","first-page":"eabc0653","DOI":"10.1126\/scisignal.abc0653","volume":"13","author":"C Gorby","year":"2020","unstructured":"Gorby, C. et al. Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses. Sci. Signal. 13, eabc0653 (2020).","journal-title":"Sci. Signal."},{"key":"746_CR155","doi-asserted-by":"publisher","first-page":"eabc8433","DOI":"10.1126\/science.abc8433","volume":"371","author":"RA Saxton","year":"2021","unstructured":"Saxton, R. A. et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10. Science 371, eabc8433 (2021).","journal-title":"Science"},{"key":"746_CR156","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.cell.2021.01.018","volume":"184","author":"CR Glassman","year":"2021","unstructured":"Glassman, C. R. et al. Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell 184, 983\u2013999 e924 (2021). Describes an approach for fine-tuning the signals of IL-12 and IL-23.","journal-title":"Cell"},{"key":"746_CR157","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41586-019-0988-7","volume":"567","author":"JL Mendoza","year":"2019","unstructured":"Mendoza, J. L. et al. Structure of the IFN\u03b3 receptor complex guides design of biased agonists. Nature 567, 56\u201360 (2019).","journal-title":"Nature"},{"key":"746_CR158","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.immuni.2021.03.008","volume":"54","author":"RA Saxton","year":"2021","unstructured":"Saxton, R. A. et al. The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design. Immunity 54, 660\u2013672 e669 (2021).","journal-title":"Immunity"},{"key":"746_CR159","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","volume":"13","author":"S Rose-John","year":"2017","unstructured":"Rose-John, S., Winthrop, K. & Calabrese, L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat. Rev. Rheumatol. 13, 399\u2013409 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"746_CR160","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MW Teng","year":"2015","unstructured":"Teng, M. W. et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719\u2013729 (2015).","journal-title":"Nat. Med."},{"key":"746_CR161","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","volume":"17","author":"S Dubois","year":"2002","unstructured":"Dubois, S., Mariner, J., Waldmann, T. A. & Tagaya, Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17, 537\u2013547 (2002).","journal-title":"Immunity"},{"key":"746_CR162","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nm.2365","volume":"17","author":"SC Wuest","year":"2011","unstructured":"Wuest, S. C. et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17, 604\u2013609 (2011).","journal-title":"Nat. Med."},{"key":"746_CR163","doi-asserted-by":"publisher","first-page":"9166","DOI":"10.1073\/pnas.0600240103","volume":"103","author":"MP Rubinstein","year":"2006","unstructured":"Rubinstein, M. P. et al. Converting IL-15 to a superagonist by binding to soluble IL-15R\u03b1. Proc. Natl Acad. Sci. USA 103, 9166\u20139171 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR164","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1074\/jbc.M508624200","volume":"281","author":"E Mortier","year":"2006","unstructured":"Mortier, E. et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta\/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J. Biol. Chem. 281, 1612\u20131619 (2006).","journal-title":"J. Biol. Chem."},{"key":"746_CR165","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4049\/jimmunol.1600019","volume":"197","author":"M Desbois","year":"2016","unstructured":"Desbois, M. et al. IL-15 trans-signaling with the superagonist RLI promotes effector\/memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists. J. Immunol. 197, 168\u2013178 (2016). Describes a covalently linked IL-15\u2013IL-15R\u03b1 super-agonist.","journal-title":"J. Immunol."},{"key":"746_CR166","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.4049\/jimmunol.1700046","volume":"198","author":"D Meghnem","year":"2017","unstructured":"Meghnem, D. et al. Cutting edge: differential fine-tuning of IL-2- and IL-15-dependent functions by targeting their common IL-2\/15R\u03b2\/\u03b3c receptor. J. Immunol. 198, 4563\u20134568 (2017).","journal-title":"J. Immunol."},{"key":"746_CR167","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.immuni.2018.03.012","volume":"48","author":"KS Burrack","year":"2018","unstructured":"Burrack, K. S. et al. Interleukin-15 complex treatment protects mice from cerebral malaria by inducing interleukin-10-producing natural k\u03b1iller cells. Immunity 48, 760\u2013772 e764 (2018).","journal-title":"Immunity"},{"key":"746_CR168","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","volume":"19","author":"JM Wrangle","year":"2018","unstructured":"Wrangle, J. M. et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 19, 694\u2013704 (2018). Describes ALT-803 (also known as N-803), an IL-15 super-agonist comprising IL-15(N72D) fused to dimeric IL-15R\u03b1\u2013IgG Fc.","journal-title":"Lancet Oncol."},{"key":"746_CR169","unstructured":"Seymour, C. FDA accepts BLA for N-803 in BCG-unresponsive non\u2013muscle invasive bladder cancer in situ. Oncology Live Urologists in Cancer Care https:\/\/www.onclive.com\/view\/fda-accepts-bla-for-n-803-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-in-situ (1 August 2022)."},{"key":"746_CR170","unstructured":"Conroy, R. FDA declines N-803 combo approval in non-muscle invasive bladder cancer. Cancer Network https:\/\/www.cancernetwork.com\/view\/fda-declines-n-803-combo-approval-in-non-muscle-invasive-bladder-cancer (11 May 2023)."},{"key":"746_CR171","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4049\/jimmunol.2100066","volume":"208","author":"MP Rubinstein","year":"2022","unstructured":"Rubinstein, M. P. et al. Phase I trial characterizing the pharmacokinetic profile of N-803, a chimeric IL-15 superagonist, in healthy volunteers. J. Immunol. 208, 1362\u20131370 (2022).","journal-title":"J. Immunol."},{"key":"746_CR172","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1084\/jem.166.4.1156","volume":"166","author":"JW Lowenthal","year":"1987","unstructured":"Lowenthal, J. W. & Greene, W. C. Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor. J. Exp. Med. 166, 1156\u20131161 (1987).","journal-title":"J. Exp. Med."},{"key":"746_CR173","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000673","volume":"8","author":"JE Lopes","year":"2020","unstructured":"Lopes, J. E. et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J. Immunother. Cancer 8, e00673 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"746_CR174","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.2337\/db20-0186","volume":"69","author":"NC Ward","year":"2020","unstructured":"Ward, N. C. et al. Persistent IL-2 receptor signaling by IL-2\/CD25 fusion protein controls diabetes in NOD mice by multiple mechanisms. Diabetes 69, 2400\u20132413 (2020).","journal-title":"Diabetes"},{"key":"746_CR175","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00262-020-02722-5","volume":"70","author":"R Hernandez","year":"2021","unstructured":"Hernandez, R. et al. Sustained IL-2R signaling of limited duration by high-dose mIL-2\/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity. Cancer Immunol. Immunother. 70, 909\u2013921 (2021). Describes a CD25\u2013IL-2 fusion protein that favours formation of a trans-dimer, prolonging half-life; in models of lupus and type 1 diabetes, it favours expansion of Treg cells but at high concentrations, it expands effector and memory T cell responses.","journal-title":"Cancer Immunol. Immunother."},{"key":"746_CR176","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002865","volume":"9","author":"R Hernandez","year":"2021","unstructured":"Hernandez, R., LaPorte, K. M., Hsiung, S., Santos Savio, A. & Malek, T. R. High-dose IL-2\/CD25 fusion protein amplifies vaccine-induced CD4+ and CD8+ neoantigen-specific T cells to promote antitumor immunity. J. Immunother. Cancer 9, e002865 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"746_CR177","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","volume":"565","author":"DA Silva","year":"2019","unstructured":"Silva, D. A. et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature 565, 186\u2013191 (2019). Describes the \u2018neokine\u2019, NL-201, which is an IL-2\/IL-15 mimetic.","journal-title":"Nature"},{"key":"746_CR178","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1073\/pnas.1217996110","volume":"110","author":"J Hou","year":"2013","unstructured":"Hou, J. et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc. Natl Acad. Sci. USA 110, 3913\u20133918 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR179","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609\u2013614 (2020). Development of DR18, a variant of IL-18 that is resistant to inhibition by IL-18BP, an IL-18 decoy receptor.","journal-title":"Nature"},{"key":"746_CR180","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3389\/fphar.2019.01490","volume":"10","author":"T Padutsch","year":"2019","unstructured":"Padutsch, T. et al. Superior Treg-expanding properties of a novel dual-acting cytokine fusion protein. Front. Pharmacol. 10, 1490 (2019).","journal-title":"Front. Pharmacol."},{"key":"746_CR181","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41586-019-1601-9","volume":"574","author":"M Findeisen","year":"2019","unstructured":"Findeisen, M. et al. Treatment of type 2 diabetes with the designer cytokine IC7Fc. Nature 574, 63\u201368 (2019).","journal-title":"Nature"},{"key":"746_CR182","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ijc.20098","volume":"110","author":"C Heuser","year":"2004","unstructured":"Heuser, C. et al. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin\u2019s lymphoma derived tumour cells. Int. J. Cancer 110, 386\u2013394 (2004).","journal-title":"Int. J. Cancer"},{"key":"746_CR183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044482","volume":"7","author":"T Jahn","year":"2012","unstructured":"Jahn, T. et al. An IL12-IL2-antibody fusion protein targeting Hodgkin\u2019s lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack. PLoS ONE 7, e44482 (2012).","journal-title":"PLoS ONE"},{"key":"746_CR184","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/1535-7163.MCT-20-0457","volume":"20","author":"SA Martomo","year":"2021","unstructured":"Martomo, S. A. et al. Single-dose anti-PD-L1\/IL-15 fusion protein KD033 generates synergistic antitumor immunity with robust tumor-immune gene signatures and memory responses. Mol. Cancer Ther. 20, 347\u2013356 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"746_CR185","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1158\/1078-0432.CCR-19-3354","volume":"26","author":"SN Quayle","year":"2020","unstructured":"Quayle, S. N. et al. CUE-101, a novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies. Clin. Cancer Res. 26, 1953\u20131964 (2020).","journal-title":"Clin. Cancer Res."},{"key":"746_CR186","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1172\/JCI67008","volume":"123","author":"EE West","year":"2013","unstructured":"West, E. E. et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 123, 2604\u20132615 (2013).","journal-title":"J. Clin. Invest."},{"key":"746_CR187","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","volume":"610","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature 610, 173\u2013181 (2022). Demonstrates that IL-2 and PD1 cooperate and that signalling via high-affinity receptors enhances antitumour immunity.","journal-title":"Nature"},{"key":"746_CR188","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","volume":"610","author":"L Codarri Deak","year":"2022","unstructured":"Codarri Deak, L. et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature 610, 161\u2013172 (2022). Describes the PD1\u2013IL-2v immunokine that maintains stem-like CD8+ cells with enhanced antitumour activity.","journal-title":"Nature"},{"key":"746_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90096-8","volume":"11","author":"KE Harris","year":"2021","unstructured":"Harris, K. E. et al. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Sci. Rep. 11, 10592 (2021).","journal-title":"Sci. Rep."},{"key":"746_CR190","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.cell.2022.02.025","volume":"185","author":"M Yen","year":"2022","unstructured":"Yen, M. et al. Facile discovery of surrogate cytokine agonists. Cell 185, 1414\u20131430 e1419 (2022). Shows an approach to rapidly discover new cytokine agonists.","journal-title":"Cell"},{"key":"746_CR191","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/sj.onc.1210368","volume":"26","author":"TA Waldmann","year":"2007","unstructured":"Waldmann, T. A. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia\/lymphoma. Oncogene 26, 3699\u20133703 (2007).","journal-title":"Oncogene"},{"key":"746_CR192","doi-asserted-by":"publisher","first-page":"8705","DOI":"10.1073\/pnas.0402653101","volume":"101","author":"B Bielekova","year":"2004","unstructured":"Bielekova, B. et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl Acad. Sci. USA 101, 8705\u20138708 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR193","doi-asserted-by":"publisher","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","volume":"10","author":"T Tanaka","year":"2017","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. Interleukin (IL-6) Immunotherapy. Cold Spring Harb. Perspect. Biol. 10, a028456 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"746_CR194","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/17512433.2022.2097905","volume":"15","author":"M Narazaki","year":"2022","unstructured":"Narazaki, M. & Kishimoto, T. Current status and prospects of IL-6-targeting therapy. Expert. Rev. Clin. Pharmacol. 15, 575\u2013592 (2022).","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"746_CR195","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.xcrm.2022.100878","volume":"4","author":"MA Huseni","year":"2023","unstructured":"Huseni, M. A. et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep. Med. 4, 100878 (2023).","journal-title":"Cell Rep. Med."},{"key":"746_CR196","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","volume":"77","author":"M Shirley","year":"2017","unstructured":"Shirley, M. Dupilumab: first global approval. Drugs 77, 1115\u20131121 (2017).","journal-title":"Drugs"},{"key":"746_CR197","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/art.41179","volume":"72","author":"RF van Vollenhoven","year":"2020","unstructured":"van Vollenhoven, R. F. et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 72, 761\u2013768 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"746_CR198","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy, S. M. Tezepelumab: first approval. Drugs 82, 461\u2013468 (2022).","journal-title":"Drugs"},{"key":"746_CR199","doi-asserted-by":"publisher","first-page":"eabo0205","DOI":"10.1126\/scitranslmed.abo0205","volume":"15","author":"A Le Floc\u2019h","year":"2023","unstructured":"Le Floc\u2019h, A. et al. Blocking common gamma chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease models. Sci. Transl. Med. 15, eabo0205 (2023).","journal-title":"Sci. Transl. Med."},{"key":"746_CR200","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jmb.2020.01.012","volume":"432","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. A synthetic human antibody antagonizes IL-18Rbeta signaling through an allosteric mechanism. J. Mol. Biol. 432, 1169\u20131182 (2020).","journal-title":"J. Mol. Biol."},{"key":"746_CR201","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips, R. L. et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell 185, 3857\u20133876 (2022).","journal-title":"Cell"},{"key":"746_CR202","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3109\/07853890.2014.882105","volume":"46","author":"HL Rajala","year":"2014","unstructured":"Rajala, H. L., Porkka, K., Maciejewski, J. P., Loughran, T. P. Jr & Mustjoki, S. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann. Med. 46, 114\u2013122 (2014).","journal-title":"Ann. Med."},{"key":"746_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7025","volume":"6","author":"C Kucuk","year":"2015","unstructured":"Kucuk, C. et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells. Nat. Commun. 6, 6025 (2015).","journal-title":"Nat. Commun."},{"key":"746_CR204","doi-asserted-by":"publisher","DOI":"10.1002\/cphg.21","author":"SA Forbes","year":"2016","unstructured":"Forbes, S. A. et al. COSMIC: high-resolution cancer genetics using the catalogue of somatic mutations in cancer. Curr. Protoc. Hum. Genet. https:\/\/doi.org\/10.1002\/cphg.21 (2016).","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"746_CR205","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrd4088","volume":"12","author":"G Miklossy","year":"2013","unstructured":"Miklossy, G., Hilliard, T. S. & Turkson, J. Therapeutic modulators of STAT signalling for human diseases. Nat. Rev. Drug Discov. 12, 611\u2013629 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"746_CR206","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234\u2013248 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"746_CR207","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.4049\/jimmunol.1401635","volume":"194","author":"PA Toniolo","year":"2015","unstructured":"Toniolo, P. A. et al. Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation. J. Immunol. 194, 3180\u20133190 (2015).","journal-title":"J. Immunol."},{"key":"746_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00920-3","volume":"7","author":"N Elumalai","year":"2017","unstructured":"Elumalai, N. et al. Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b. Sci. Rep. 7, 819 (2017).","journal-title":"Sci. Rep."},{"key":"746_CR209","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct. Target. Ther. 6, 402 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"746_CR210","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41587-021-01173-2","volume":"40","author":"K Garber","year":"2022","unstructured":"Garber, K. The PROTAC gold rush. Nat. Biotechnol. 40, 12\u201316 (2022).","journal-title":"Nat. Biotechnol."},{"key":"746_CR211","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai, L. et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36, 498\u2013511 e417 (2019).","journal-title":"Cancer Cell"},{"key":"746_CR212","doi-asserted-by":"publisher","first-page":"115326","DOI":"10.1016\/j.bmc.2020.115326","volume":"28","author":"RR Shah","year":"2020","unstructured":"Shah, R. R. et al. Hi-JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs. Bioorg. Med. Chem. 28, 115326 (2020). Development of PROTACs.","journal-title":"Bioorg. Med. Chem."},{"key":"746_CR213","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","volume":"41","author":"K Pance","year":"2023","unstructured":"Pance, K. et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat. Biotechnol. 41, 273\u2013281 (2023).","journal-title":"Nat. Biotechnol."},{"key":"746_CR214","doi-asserted-by":"publisher","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","volume":"13","author":"C Hotz","year":"2021","unstructured":"Hotz, C. et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl. Med. 13, eabc7804 (2021).","journal-title":"Sci. Transl. Med."},{"key":"746_CR215","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62\u201368 (2015).","journal-title":"Science"},{"key":"746_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24987-9","volume":"12","author":"JL Ptacin","year":"2021","unstructured":"Ptacin, J. L. et al. An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism. Nat. Commun. 12, 4785 (2021).","journal-title":"Nat. Commun."},{"key":"746_CR217","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2022-eular.2244","volume":"81","author":"N Tchao","year":"2022","unstructured":"Tchao, N. et al. Efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory T cells in patients with SLE: final results of a phase 1b multiple ascending dose study. Ann. Rheum. Dis. 81, 1343\u20131344 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"746_CR218","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1479-5876-11-5","volume":"11","author":"J Laurent","year":"2013","unstructured":"Laurent, J. et al. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2\/anti-DNA fusion protein. J. Transl. Med. 11, 5 (2013).","journal-title":"J. Transl. Med."},{"key":"746_CR219","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003155","volume":"10","author":"R Merchant","year":"2022","unstructured":"Merchant, R. et al. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate. J. Immunother. Cancer 10, e003155 (2022).","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl. 13","key":"746_CR220","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1158\/1538-7445.AM2021-1744","volume":"81","author":"J Emmerich","year":"2021","unstructured":"Emmerich, J. et al. STK-012, an alpha\/beta selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor. Cancer Res. 81 (Suppl. 13), 1744 (2021).","journal-title":"Cancer Res."},{"key":"746_CR221","doi-asserted-by":"publisher","first-page":"1913791","DOI":"10.1080\/19420862.2021.1913791","volume":"13","author":"I Waldhauer","year":"2021","unstructured":"Waldhauer, I. et al. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs 13, 1913791 (2021).","journal-title":"MAbs"},{"key":"746_CR222","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1277306","volume":"6","author":"C Klein","year":"2017","unstructured":"Klein, C. et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 6, e1277306 (2017).","journal-title":"Oncoimmunology"},{"key":"746_CR223","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1158\/1078-0432.CCR-11-1817","volume":"17","author":"MN Fishman","year":"2011","unstructured":"Fishman, M. N. et al. Phase I trial of ALT-801, an interleukin-2\/T-cell receptor fusion protein targeting p53 (aa264-272)\/HLA-A*0201 complex, in patients with advanced malignancies. Clin. Cancer Res. 17, 7765\u20137775 (2011).","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 12","key":"746_CR224","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1158\/1538-7445.AM2022-3518","volume":"82","author":"KD Moynihan","year":"2022","unstructured":"Moynihan, K. D. et al. AB248 is a CD8+ T cell selective IL-2 designed for superior safety and anti-tumor efficacy [abstract]. Cancer Res. 82 (Suppl. 12), 3518 (2022).","journal-title":"Cancer Res."},{"key":"746_CR225","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/search?term=NCT04710043 (2023)."},{"key":"746_CR226","doi-asserted-by":"publisher","first-page":"541619","DOI":"10.3389\/fimmu.2020.541619","volume":"11","author":"KB DeOca","year":"2020","unstructured":"DeOca, K. B., Moorman, C. D., Garcia, B. L. & Mannie, M. D. Low-zone IL-2 signaling: fusion proteins containing linked CD25 and IL-2 domains sustain tolerogenic vaccination in vivo and promote dominance of FOXP3+ Tregs in vitro. Front. Immunol. 11, 541619 (2020).","journal-title":"Front. Immunol."},{"issue":"Suppl. 16","key":"746_CR227","doi-asserted-by":"publisher","first-page":"TPS2697","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2697","volume":"40","author":"M McKean","year":"2022","unstructured":"McKean, M. et al. A first-in-human, multicenter, phase 1\/2 open-label study of XTX202, a masked and tumor-selective recombinant human interleukin-2 (IL-2) protein, in patients with advanced solids tumors [abstract]. J. Clin. Oncol. 40 (Suppl. 16), TPS2697 (2022).","journal-title":"J. Clin. Oncol."},{"key":"746_CR228","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/art.40413","volume":"70","author":"R Fischer","year":"2018","unstructured":"Fischer, R. et al. Selective activation of tumor necrosis factor receptor ii induces antiinflammatory responses and alleviates experimental arthritis. Arthritis Rheumatol. 70, 722\u2013735 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"746_CR229","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002024","volume":"9","author":"T Miyazaki","year":"2021","unstructured":"Miyazaki, T. et al. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy. J. Immunother. Cancer 9, e002024 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"746_CR230","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.4049\/jimmunol.0901244","volume":"183","author":"X Zhu","year":"2009","unstructured":"Zhu, X. et al. Novel human interleukin-15 agonists. J. Immunol. 183, 3598\u20133607 (2009).","journal-title":"J. Immunol."},{"key":"746_CR231","doi-asserted-by":"publisher","first-page":"23869","DOI":"10.1074\/jbc.M116.733600","volume":"291","author":"B Liu","year":"2016","unstructured":"Liu, B. et al. A novel fusion of ALT-803 (interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses. J. Biol. Chem. 291, 23869\u201323881 (2016).","journal-title":"J. Biol. Chem."},{"key":"746_CR232","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003388","volume":"9","author":"K Conlon","year":"2021","unstructured":"Conlon, K. et al. Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. J. Immunother. Cancer 9, e003388 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"746_CR233","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/annonc\/mdv173","volume":"26","author":"O Tredan","year":"2015","unstructured":"Tredan, O. et al. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann. Oncol. 26, 1353\u20131362 (2015).","journal-title":"Ann. Oncol."},{"key":"746_CR234","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ijbiomac.2016.02.006","volume":"86","author":"JY Lim","year":"2016","unstructured":"Lim, J. Y. et al. Biophysical stability of hyFc fusion protein with regards to buffers and various excipients. Int. J. Biol. Macromol. 86, 622\u2013629 (2016).","journal-title":"Int. J. Biol. Macromol."},{"issue":"Suppl. 16","key":"746_CR235","first-page":"1081","volume":"40","author":"J Sohn","year":"2019","unstructured":"Sohn, J. et al. Phase 1b\/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R\/R) metastatic triple-negative breast cancer (mTNBC): the KEYNOTE-899 study [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 1081\u20131081 (2022).","journal-title":"J. Clin. Oncol."},{"key":"746_CR236","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.4049\/jimmunol.177.7.4458","volume":"177","author":"JC Sun","year":"2006","unstructured":"Sun, J. C., Lehar, S. M. & Bevan, M. J. Augmented IL-7 signaling during viral infection drives greater expansion of effector T cells but does not enhance memory. J. Immunol. 177, 4458\u20134463 (2006).","journal-title":"J. Immunol."},{"key":"746_CR237","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.8","volume":"4","author":"J Hsieh","year":"2015","unstructured":"Hsieh, J. et al. A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency. Clin. Transl. Immunol. 4, e37 (2015).","journal-title":"Clin. Transl. Immunol."},{"key":"746_CR238","first-page":"A341","volume":"8","author":"W Dower","year":"2020","unstructured":"Dower, W. et al. MDK1319\/MDK-701: a potent fully efficacious peptidyl agonist of IL-7R alpha gamma C, designed with no reference to cytokine or receptor structure and unrelated to IL-7, fused to an FC-domain for PK enhancement. J. Immunother. Cancer 8, A341\u2013A342 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"746_CR239","first-page":"A657","volume":"10","author":"R Friend","year":"2022","unstructured":"Friend, R., Baxter, B., Park, I. A., Cwirla, S. & Barrett, R. A phase 1 single ascending dose study evaluating the safety, tolerability, and pharmacodynamic effects of Mdk-703, an Il-7 mimetic with extended half-life. J. Immunother. Cancer 10, A657 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"746_CR240","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/1535-7163.MCT-16-0111","volume":"15","author":"Y Song","year":"2016","unstructured":"Song, Y. et al. In vivo antitumor activity of a recombinant IL7\/IL15 hybrid cytokine in mice. Mol. Cancer Ther. 15, 2413\u20132421 (2016).","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl. 16","key":"746_CR241","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/1538-7445.AM2020-910","volume":"80","author":"A Morello","year":"2020","unstructured":"Morello, A. et al. A novel bifunctional anti-PD-1 IL-7 fusion protein to reinvigorate exhausted T cell and disarms Treg suppressive activity [abstract]. Cancer Res. 80 (Suppl. 16), 910 (2020).","journal-title":"Cancer Res."},{"key":"746_CR242","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3389\/fimmu.2020.00832","volume":"11","author":"S Shen","year":"2020","unstructured":"Shen, S. et al. Engineered IL-21 cytokine muteins fused to anti-PD-1 antibodies can improve CD8+ T cell function and anti-tumor immunity. Front. Immunol. 11, 832 (2020).","journal-title":"Front. Immunol."},{"key":"746_CR243","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21241-0","volume":"12","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nat. Commun. 12, 951 (2021).","journal-title":"Nat. Commun."},{"key":"746_CR244","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1182\/blood-2016-09-738211","volume":"129","author":"S Bhatt","year":"2017","unstructured":"Bhatt, S. et al. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity. Blood 129, 2246\u20132256 (2017).","journal-title":"Blood"},{"key":"746_CR245","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/neuonc\/noac285","volume":"25","author":"JH Sampson","year":"2023","unstructured":"Sampson, J. H. et al. Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: results of a phase 2b trial. Neuro Oncol. 25, 1085\u20131097 (2023).","journal-title":"Neuro Oncol."},{"key":"746_CR246","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1182\/blood.V128.22.4165.4165","volume":"128","author":"YH Kim","year":"2016","unstructured":"Kim, Y. H. et al. A single-arm phase 2A study of NM-IL-12 (rHu-IL12) in patients with mycosis fungoides-type CTCL (MF) undergoing low-dose total skin electron beam therapy (LD-TSEBT) [abstract]. Blood 128, 4165 (2016).","journal-title":"Blood"},{"key":"746_CR247","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.medj.2023.03.007","volume":"4","author":"E Gutierrez","year":"2023","unstructured":"Gutierrez, E. et al. An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. Med 4, 326\u2013340.e5 (2023).","journal-title":"Med"},{"key":"746_CR248","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","volume":"25","author":"J Strauss","year":"2019","unstructured":"Strauss, J. et al. First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors. Clin. Cancer Res. 25, 99\u2013109 (2019).","journal-title":"Clin. Cancer Res."},{"key":"746_CR249","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/ITT.S306150","volume":"10","author":"JW Greiner","year":"2021","unstructured":"Greiner, J. W., Morillon, Y. M. 2nd & Schlom, J. NHS-IL12, a tumor-targeting immunocytokine. Immunotargets Ther. 10, 155\u2013169 (2021).","journal-title":"Immunotargets Ther."},{"key":"746_CR250","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jbiotec.2018.12.004","volume":"291","author":"T Ongaro","year":"2019","unstructured":"Ongaro, T. et al. A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors. J. Biotechnol. 291, 17\u201325 (2019).","journal-title":"J. Biotechnol."},{"key":"746_CR251","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0092-8674(00)81443-9","volume":"93","author":"X Chen","year":"1998","unstructured":"Chen, X. et al. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93, 827\u2013839 (1998).","journal-title":"Cell"},{"key":"746_CR252","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0896-6273(91)90258-2","volume":"7","author":"JF Bazan","year":"1991","unstructured":"Bazan, J. F. Neuropoietic cytokines in the hematopoietic fold. Neuron 7, 197\u2013208 (1991).","journal-title":"Neuron"},{"key":"746_CR253","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1084\/jem.20080526","volume":"205","author":"GA Martins","year":"2008","unstructured":"Martins, G. A., Cimmino, L., Liao, J., Magnusdottir, E. & Calame, K. Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J. Exp. Med. 205, 1959\u20131965 (2008).","journal-title":"J. Exp. Med."},{"key":"746_CR254","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140694","volume":"10","author":"B Tomkowicz","year":"2015","unstructured":"Tomkowicz, B. et al. TIM-3 suppresses anti-CD3\/CD28-induced TCR activation and IL-2 expression through the NFAT signaling pathway. PLoS ONE 10, e0140694 (2015).","journal-title":"PLoS ONE"},{"key":"746_CR255","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057\u20131061 (2003).","journal-title":"Science"},{"key":"746_CR256","doi-asserted-by":"publisher","first-page":"12111","DOI":"10.1073\/pnas.1714019114","volume":"114","author":"P Li","year":"2017","unstructured":"Li, P. et al. STAT5-mediated chromatin interactions in superenhancers activate IL-2 highly inducible genes: functional dissection of the Il2ra gene locus. Proc. Natl Acad. Sci. USA 114, 12111\u201312119 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"746_CR257","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature23875","volume":"549","author":"DR Simeonov","year":"2017","unstructured":"Simeonov, D. R. et al. Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature 549, 111\u2013115 (2017).","journal-title":"Nature"},{"key":"746_CR258","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1126\/science.273.5276.794","volume":"273","author":"X Xu","year":"1996","unstructured":"Xu, X., Sun, Y. L. & Hoey, T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 273, 794\u2013797 (1996).","journal-title":"Science"},{"key":"746_CR259","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1002\/j.1460-2075.1996.tb00946.x","volume":"15","author":"U Vinkemeier","year":"1996","unstructured":"Vinkemeier, U. et al. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J. 15, 5616\u20135626 (1996).","journal-title":"EMBO J."},{"key":"746_CR260","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1128\/MCB.19.3.1910","volume":"19","author":"S John","year":"1999","unstructured":"John, S., Vinkemeier, U., Soldaini, E., Darnell, J. E. Jr. & Leonard, W. J. The significance of tetramerization in promoter recruitment by Stat5. Mol. Cell Biol. 19, 1910\u20131918 (1999).","journal-title":"Mol. Cell Biol."},{"key":"746_CR261","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature14154","volume":"520","author":"G Vahedi","year":"2015","unstructured":"Vahedi, G. et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature 520, 558\u2013562 (2015).","journal-title":"Nature"},{"key":"746_CR262","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934\u2013947 (2013).","journal-title":"Cell"},{"key":"746_CR263","first-page":"1379","volume":"138","author":"VL Godfrey","year":"1991","unstructured":"Godfrey, V. L., Wilkinson, J. E. & Russell, L. B. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am. J. Pathol. 138, 1379\u20131387 (1991).","journal-title":"Am. J. Pathol."},{"key":"746_CR264","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.4049\/jimmunol.153.8.3764","volume":"153","author":"PJ Blair","year":"1994","unstructured":"Blair, P. J. et al. CD4+CD8\u2212 T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. J. Immunol. 153, 3764\u20133774 (1994).","journal-title":"J. Immunol."},{"key":"746_CR265","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi, S. et al. Regulatory T cells and human disease. Annu. Rev. Immunol. 38, 541\u2013566 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"746_CR266","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.2337\/db14-1322","volume":"64","author":"A Yu","year":"2015","unstructured":"Yu, A. et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 64, 2172\u20132183 (2015).","journal-title":"Diabetes"},{"key":"746_CR267","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110\u20132121 (2011).","journal-title":"N. Engl. J. Med."},{"key":"746_CR268","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3389\/fimmu.2018.00786","volume":"9","author":"M Mizui","year":"2018","unstructured":"Mizui, M. & Tsokos, G. C. Targeting regulatory T cells to treat patients with systemic lupus erythematosus. Front. Immunol. 9, 786 (2018).","journal-title":"Front. Immunol."},{"key":"746_CR269","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22, 991\u2013993 (2016).","journal-title":"Nat. Med."},{"key":"746_CR270","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141\u2013149 (2020). Efficacy of low-dose IL-2 related to systemic lupus erythematosis.","journal-title":"Ann. Rheum. Dis."},{"key":"746_CR271","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C von Spee-Mayer","year":"2016","unstructured":"von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 75, 1407\u20131415 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"746_CR272","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1, 295\u2013305 (2013).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"746_CR273","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","volume":"58","author":"M Rosenzwajg","year":"2015","unstructured":"Rosenzwajg, M. et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J. Autoimmun. 58, 48\u201358 (2015).","journal-title":"J. Autoimmun."},{"key":"746_CR274","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s00125-020-05200-w","volume":"63","author":"M Rosenzwajg","year":"2020","unstructured":"Rosenzwajg, M. et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I\/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia 63, 1808\u20131821 (2020).","journal-title":"Diabetologia"},{"key":"746_CR275","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147474","volume":"6","author":"S Dong","year":"2021","unstructured":"Dong, S. et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight 6, e147474 (2021).","journal-title":"JCI Insight"}],"updated-by":[{"DOI":"10.1038\/s41573-024-01055-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000}}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00746-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T15:05:06Z","timestamp":1726844706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00746-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":275,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1038\/s41573-023-00746-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41573-024-01055-7","asserted-by":"object"}]},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"2 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41573-024-01055-7","URL":"https:\/\/doi.org\/10.1038\/s41573-024-01055-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.J.L. is an inventor on patents related to IL-2 partial agonists. J.X.L. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}